Viral Vector & Plasmid DNA Manufacturing Market to Reach USD 24.6 Billion by 2032

ALABASTER, Ala. - March 31, 2025 - PRLog -- Market Overview

Viral vectors and plasmid DNA manufacturing market are critical components in the development of gene therapies, vaccines, and advanced biopharmaceutical treatments. The rising prevalence of genetic disorders, cancers, and infectious diseases is accelerating demand for high-quality viral vectors and plasmid DNA for research, clinical trials, and commercial therapeutic applications.

Leading Companies in the Viral Vector & Plasmid DNA Manufacturing Market

The market is highly competitive, with major biotech and pharmaceutical firms investing in state-of-the-art manufacturing facilities, partnerships, and contract development & manufacturing (CDMO) services.

Key Market Players:

• Lonza Group AG
• Thermo Fisher Scientific Inc.
• Merck KGaA (MilliporeSigma)
• Catalent Inc.
• WuXi AppTec
• Oxford Biomedica
• Takara Bio Inc.
• Cobra Biologics
• Charles River Laboratories International Inc.
• VGXI Inc.

These companies are expanding their biomanufacturing capabilities and investing in innovative viral vector technologies to meet the growing demand for cell & gene therapies.

Major Growth Drivers of the Viral Vector & Plasmid DNA Manufacturing Market

1. Rising Demand for Gene and Cell Therapy Treatments

• The FDA and EMA approvals of gene therapies have fueled demand for high-quality viral vectors and plasmid DNA.

2. Increased Investment in Biotechnology & Biopharmaceutical R&D

• Governments and private investors are funding research into genomic medicine, rare disease treatments, and regenerative therapies.

View Source For More Information: https://www.acumenresearchandconsulting.com/viral-vector-and-plasmid-dna-manufacturing-market

Key Challenges Facing the Viral Vector & Plasmid DNA Manufacturing Industry

1. High Production Costs & Complex Manufacturing Processes

• Viral vector and plasmid DNA manufacturing require specialized facilities, strict quality controls, and advanced bioprocessing technologies, leading to high costs and long production timelines.

2. Regulatory Hurdles & Compliance Issues

• Stringent regulatory requirements for gene therapy products and viral vector-based treatments create challenges for product approval and commercialization.

Future Outlook & Opportunities

Expansion of Gene Therapy Approvals – More regulatory approvals for gene-based treatments will drive demand for high-quality viral vectors and plasmid DNA.

Advancements in CRISPR & Gene Editing – Growing use of CRISPR-Cas9 for genome engineering and disease treatment will support market growth.

Rise of AI-Driven Biomanufacturing – AI-based process automation and analytics will enhance efficiency and scalability in viral vector production.

Click Here For More Details: https://www.globenewswire.com/news-release/2019/10/08/1926612/0/en/Plasmid-DNA-Manufacturing-Market-Size-to-Hit-US-300-Mn-by-2026.html